Glycemic Variability of Combination Therapies in T2DM
ConditionType 2 Diabetes Mellitus (T2DM)
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorJW Pharmaceutical
About this trial
Glycemic Variability of Combination Therapies in T2DM
Eligibility criteria
Qualifiers
Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.
Disqualifiers
History of acute or chronic metabolic acidosis
Moderate to severe renal impairment (eGFR < 45 mL/min/1.73m²)
Severe hepatic impairment
History of heart failure (NYHA Class III/IV)
Trial design
Treatments tested in this trial
- Empagliflozin/Metformin
- Anagliptin
- Metformin
- Empagliflozin/Linagliptin
Treatment groups
178 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov